EGFR and non-small cell lung carcinoma: Although gefitinib, an EGFR Tyr kinase inhibitor (TKI), was used to treat NSCLC patients 13 years ago [7], highly metastatic properties and drug resistance during TKI therapy still cause poor prognoses of lung cancer patients [8, 9].